 Approximately 2,500 high-risk patients with an elevated LDL-C level 2.5 mmolL will be enrolled. Patients meeting all inclusion criteria and having none of the exclusion criteria at Visit 1 Screening will be included. Eligible patients that agree to participate and sign an informed consent will be treated with appropriate treatment optimization including the use of ezetimibe on achieving Study Schematics Table 1. 